Alterity Therapeutics (ATH) Q1 2026 TU earnings summary

Executive summary

• Positive clinical results for ATH434 in both double-blind and open-label Phase 2 trials for Multiple System Atrophy (MSA), with efficacy signals at high dose levels and similar treatment effects in advanced and earlier-stage patients.

• Independent commercial assessment estimates a USD $2.4 billion worldwide peak sales opportunity for ATH434 in MSA, reflecting strong physician interest and market potential.

• Active engagement with the FDA, leveraging Fast Track Designation, to align on nonclinical, CMC, and clinical development requirements for Phase 3 initiation, with key meetings scheduled through mid-2026.

Financial highlights

• Cash balance as of 30 September 2025 was A$54.56M, up from A$40.66M at the start of the quarter.

• Operating cash outflows for the quarter totaled A$5.34M, primarily driven by R&D, staff, and administrative costs.

• Gross proceeds of A$20M were raised via a strategic placement to healthcare-focused funds, strengthening the balance sheet.

Outlook and guidance

• Series of regulatory meetings with the FDA are planned, culminating in an End-of-Phase 2 meeting in mid-2026 to finalize Phase 3 trial design and requirements.

• Estimated funding runway of 10.2 quarters based on current cash position and operating outflows.